Fenster schließen  |  Fenster drucken

[posting]40819985[/posting]Hallo,

hier sind zwei frische Analystenmeinungen zum Thema:

XOMA Limited: Ladenburg reviews interim results from XOMA-052 Phase IIa study

Ladenburg notes, although this was a small 74 patient trial, preliminary three-month interim data show promising results with a 49% CRP (C-reactive protein) reduction and no drug-related adverse events. This randomized, placebo-controlled, six-month Phase IIa study of Type 2 diabetic patients was designed to evaluate the safety and PK of XOMA-052, but results show a positive trend in the reduction of CRP and Hba1c. Firm believes the CRP lowering properties of XOMA-052 (also seen in earlier studies) are important, especially since a sustained, continued modulating effect could improve cardiovascular outcomes in diabetic patients. Importantly, XOMA-052 exhibited a clean safety profile and no drug-related adverse events were observed in this study.

Hier ist man also insgesamt sehr zufrieden mit den Ergebnissen.


XOMA Limited: Phase IIa data provides no evidence of anti-diabetic activity; data not conclusive - RBC Capital Mkts

RBC had low expectations for XOMA 052 Phase IIa results given the small number of patients (74) and the short 3-month treatment duration. Nevertheless, the results are disappointing with no meaningful benefit in HbA1c. The upcoming Phase IIb data in diabetes should be more conclusive in determining whether or not XOMA 052 has a path forward in diabetes. Firm stands by its recent upgrade (January 4) and would buy on weakness as the overall risk to XOMA from these data has been diminished by its recent financing and deal with Servier, which will largely fund the Behcet's opportunity and provide the quickest path to market.


Hier zeigt sich die Enttäuschung in Bezug auf die miesen Hämoglobin-Resultate deutlich, dennoch wird aufgrund der aktuellen Kooperationsvereinbarung mit Servier am Ratung festgehalten und auch zum Nachkauf bei Schwäche geraten.



Insgesamt also unter dem Strich eher positive Analystenreaktionen.
 
aus der Diskussion: Xoma 200-Prozent-Chance !!!! ????? !!!!!
Autor (Datum des Eintrages): Circle_Jerk  (07.01.11 15:11:01)
Beitrag: 14,688 von 16,519 (ID:40820162)
Alle Angaben ohne Gewähr © wallstreetONLINE